Rimonabant clinical trials
Rimonabant is named as an intervention in 2 current clinical trials in our Spain register. None are recruiting at the moment. The most common phase is Phase 1/2. The lead sponsor is Sinfatin S.L. The most-studied condition is Cervical Spinal Cord Injury. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Rimonabant is approved
All regulators →Of the three regulators tracked here, the first to approve Rimonabant was the EU, on 19 Jun 2006.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
NICE appraisals of Rimonabant
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Rimonabant. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Rimonabant for the treatment of overweight and obese adults NICE TA144 | Optimised | 23 Jun 2008 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Rimonabant
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Rimonabant
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Rimonabant for Improving Walking Ability in Patients With Chronic Stroke
NCT07913763 · ClinicalTrials.gov ↗ · Chronic Stroke
|
Phase 2 | Not yet open | Sinfatin S.L | Spain |
|
Effect of Rimonabant on Hand Function in Patients With Spinal Cord Injury
NCT07843108 · ClinicalTrials.gov ↗ · Cervical Spinal Cord Injury
|
Phase 1/2 | Active, closed | Sinfatin S.L | Spain |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Rimonabant in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Rimonabant. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients with Post-COVID-19 Syndrome (RIMOCOVID-1)
2023-507870-42-00 · Virus Diseases
|
Phase 2 | Ongoing | Sinfatin S.L | Spain |
Conditions studied with Rimonabant
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Sinfatin S.L | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Spain | 2 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Questions about Rimonabant trials
How many clinical trials are testing Rimonabant?
2 current trials in our Spain register name Rimonabant as a drug or biological intervention, as of the registry sync on 4 November 2026. Completed and withdrawn studies are not counted.
Are Rimonabant trials recruiting patients?
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors Rimonabant clinical trials?
The lead sponsor is Sinfatin S.L. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rimonabant works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rimonabant works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rimonabant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 4 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.